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Abstract
Background: CBFA2T3-GLIS2 is a fusion gene found in 17% of non-Down syndrome acute megakaryoblastic
leukemia (non-DS AMKL, FAB M7) and in 8% of pediatric cytogenetically normal acute myeloid leukemia (CN-AML, in
association with several French-American-British (FAB) subtypes). Children with AML harboring this aberration have a
poor outcome, regardless of the FAB subtype. This fusion gene drives a peculiar expression pattern and leads
to overexpression of some of Hedgehog-related genes. GLI-similar protein 2 (GLIS2) is closely related to the GLI family,
the final effectors of classic Hedgehog pathway. These observations lend compelling support to the application of GLI
inhibitors in the treatment of AML with the aberration CBFA2T3-GLIS2. GANT61 is, nowadays, the most potent inhibitor
of GLI family proteins.
Methods: We exposed to GANT61 AML cell lines and primary cells positive and negative for CBFA2T3-GLIS2
and analyzed the effect on cellular viability, induction of apoptosis, cell cycle, and expression profile.
Results: As compared to AML cells without GLIS2 fusion, GANT61 exposure resulted in higher sensitivity of
both cell lines and primary AML cells carrying CBFA2T3-GLIS2 to undergo apoptosis and G1 cell cycle arrest.
Remarkably, gene expression studies demonstrated downregulation of GLIS2-specific signature genes in both
treated cell lines and primary cells, in comparison with untreated cells. Moreover, chromatin immunoprecipitation
analysis revealed direct regulation by GLIS2 chimeric protein of DNMT1 and DNMT3B, two genes implicated in
important epigenetic functions.
Conclusions: Our findings indicate that the GLI inhibitor GANT61 may be used to specifically target the CBFA2T3-GLIS2
fusion gene in pediatric AML.
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Findings
Pediatric acute myeloid leukemia (AML) carrying
CBFA2T3-GLIS2 fusion gene deserves particular interest,
being associated with a grim prognosis in all the reports
published so far [1–3]. The incidence of this aberration
is 17 and 8% in pediatric non-Down syndrome acute
megakaryoblastic and in pediatric cytogenetically normal
AML, respectively [1–3]. The expression profile of
CBFA2T3-GLIS2 is associated with upregulation of both
Hedgehog (HH) and bone morphogenic protein (BMP)
signaling [1, 4].
The protein GLIS2 shares a highly homologous zinc
finger domain with members of the GLI proteins, the
final effectors of classic Hedgehog pathway. GANT61 is
a GLI inhibitor showing a potent effect on the inhibition
of transcription activity of GLI proteins, blocking their
binding to DNA [5–8]. Considering the high homology
of the DNA-binding domain between GLIS2 and GLI
family proteins, we hypothesized that GANT61 might be
used to specifically target the CBFA2T3-GLIS2 fusion
gene in pediatric AML.
In the present study, we investigated the in vitro ef-
fects of GANT61 on AML cell lines and primary cells
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from AML patients harboring the CBFA2T3-GLIS2
fusion gene.
The materials and methods are detailed in Additional
file 1. Molecular analysis of CBFA2T3-GLIS2 fusion gene
is reported in Additional file 2: Figure S1. Genetic fea-
tures of control AML cell lines without GLIS2 fusion are
reported in Additional file 3: Table S1.
Our results showed that AML cell lines with
CBFA2T3-GLIS2 fusion gene have a higher sensitivity to
GANT61 than other AML cell lines without this genetic
aberration (Fig. 1a). Similar results were obtained on pri-
mary leukemia cells isolated from AML patients, being
the IC50 of the GLIS2-positive leukemia and negative
primary cells 13.6 and 41.6 μM, respectively (Fig. 1b).
Treatment with GANT61 induced an increase of
about 30% of apoptotic cells (Fig. 1c) and block of cell
cycle in G0/G1 phase only in M07e and WSU-AML
lines positive to CBFA2T3-GLIS2 (Fig. 1d and Additional
file 4: Figure S2).
We further analyzed the expression profile of cell lines
and primary cells following GANT61 treatment.
Through qPCR, we demonstrated that GANT61 treat-
ment led to a significant reduction of the expression of
BMP2 and GLIS2 (Fig. 2a, b). In order to fully
Fig. 1 a IC50 of CBFA2T3-GLIS2 and negative cell lines 72 h after GANT61 exposure. b Dose-response curves after 72 h of GANT61 treatment of
primary cells derived from patients with acute myeloid leukemia (AML) either positive or negative for CBFA2T3-GLIS2 fusion gene. *p < 0.05 c Flow
cytometric analysis of Annexin V FITC/PI-stained AML cell lines treated for 24 h with 20 μM of GANT61. The percentages of early apoptotic cells
(Annexin V FITC+/PI−, lower right quadrant) and late apoptotic/necrotic cells (Annexin V FITC+/PI+, upper right quadrant) are indicated. NT sample
treated with vehicle alone (DMSO). d Cell cycle analysis. Flow cytometric analysis of PI-stained AML cell lines carrying the CBFA2T3-GLIS2 fusion
gene after 48 h of treatment with GANT61. NT sample treated with vehicle alone (DMSO)
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characterize the effect of GANT61 treatment on whole
transcriptome profile of CBFA2T3-GLIS2-positive cells,
gene expression was assessed by microarray analysis.
After GANT61 treatment, the expression of target
genes of CBFA2T3-GLIS2, such as CRISP3, GATA3,
H2AFY, or NCAM1(CD56) was significantly downreg-
ulated (p < 0.05) (Fig. 2c). Moreover additional genes
were downregulated by the treatment with GANT61
(p < 0.05), as for example, genes involved in cell cycle
control, such as CDC25A, CDC7, CDCA2, and CCNA2.
The expression of these genes is required for progression
through cell cycle, and their expression is aberrant in
AML, as well as in other malignancies [9, 10]. In our
model, the expression of these genes is downregulated fol-
lowing GANT61 treatment, this partly explaining the cell
cycle arrest observed in AML cell lines with GLIS2 fusion
after GANT61 treatment (Fig. 1d). Genes involved in cell
proliferation (KIF14, MELK, MCM10, NUF2) and epigen-
etic regulators namely DNMT1 and DNMT3B were also
present. Considering the particular interest of these DNA
methyltransferase genes, we performed chromatin im-
munoprecipitation (ChIP) analysis using a CBFA2T3-
specific antibody on WSU-AML and M07e cell lines.
Our findings showed that CBFA2T3-GLIS2 fusion
protein directly binds to the proximal promoter of
DNMT1 and DNMT3B, positively regulating their ex-
pression (Fig. 2d). Overexpression of DNMT genes
could lead to DNA hypermethylation and could be
involved in the leukemogenesis process.
Since in the classic Hedgehog signaling pathway,
several target genes involved in feedback mechanisms
(HHIP, PTCH1, GLI1) have been described; we hy-
pothesized that CBFA2T3-GLIS2 chimeric protein
could regulate wild-type GLIS2 protein with the same
feedback mechanism. Western blotting analysis con-
firmed the presence of chimeric protein and showed
also the presence of wild-type GLIS2. These results
may point to the role of the fusion protein in regulat-
ing wild-type GLIS2. Following GANT61 treatment,
the expression of both proteins was decreased with
respect to untreated samples, suggesting that GANT61
treatment targeted both CBFA2T3-GLIS2 fusion protein
and also wild-type GLIS2 expression (Fig. 2e). Moreover,
other AML cell lines not carrying the CBFA2T3-GLIS2 fu-
sion gene did not show expression of GLIS2 (data
not shown).
Fig. 2 Quantitative PCR of selected mediators of GLIS2 pathway a BMP2 and b GLIS2 after 48 h treatment with GANT61. *p < 0.05; **p < 0.01;
***p < 0.001. c Hierarchical clustering of genes differentially expressed between untreated and treated AML leukemia blast cells and cell lines,
with a p value <0.05. d ChIP analysis, performed on WSU-AML cell line showed around five-fold enrichment of chimeric protein on DNMT1,
DNMT3B, and NCAM1 promoters. e Western blot analysis showing the decrease of GLIS2 protein and CBFA2T3-GLIS chimeric protein in samples
treated with GANT61. Thirty micrograms of protein were blotted to each lane. Antibody to β-actin served as a loading control. The Relative
Induction (Rel Ind) is the amount of protein present in treated samples relative to untreated cells after normalizing to β-actin density
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On the other hand, western blotting analysis showed
that expression of GLI1 and GLI2 did not decrease fol-
lowing GANT61 treatment (Additional file 5: Figure S3).
Another study demonstrated a high sensitivity of this
subgroup of AML with GLIS2 fusion to Aurora A kinase
(AURKA) inhibitors [4]. We therefore investigated the
effect of GANT61 and AURKA inhibitor MK-0457 in
M07e and WSU-AML cell lines carrying the CBFA2T3-
GLIS2 fusion gene. Cell lines were incubated for 48 h
with either single drugs or a combination of the two
drugs at a constant ratio of 1:10 (GANT61:MK-0457).
The combined treatment showed a higher cytotoxic
effect when compared to each single drug, and the two
inhibitors displayed a synergistic effect on cell growth, as
indicated by the CI value (Additional file 6: Figure S4).
This work provides preliminary data from preclinical
in vitro and ex vivo studies targeting pediatric AML
with CBFA2T3-GLIS2 fusion gene. Although further in-
vestigation will be required to confirm these results,
our experience with GANT61 represents a preliminary
background for further evaluating in vivo the inhibition
of GLIS2-mediated transcription in AML harboring the
CBFA2T3-GLIS2 fusion gene.
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